


# CD(分化簇) 细胞标志物







**CD Markers:** CD1...CD370  
中和封闭, CD标志物蛋白

[bioxcell.com](http://bioxcell.com)







# CD Marker 体内抗体, CD1...CD370





| 靶标                               | 反应种属         | 应用类型  | 克隆号                                   | InVivoMab   | InVivoPlus |
|----------------------------------|--------------|---|---------------------------------------|-------------|------------|
| CD1a                             | human        | <i>in vitro</i> CD1a blockade, FC   | OKT-6                                 | BE0211      |            |
| CD1d (CD1.1)                     | mouse        | <i>in vivo</i> CD1d neutralization  | 19G11                                 | BE0000      |            |
| CD1d (CD1.1)                     | mouse        | iNKT cell neutralization, <i>in vivo</i> CD1d blockade, FC  | 20H2 (HB323)                          | BE0179      |            |
| CD3                              | human        | <i>in vitro</i> T cell stimulation/activation, <i>in vivo</i> T cell depletion in humanized mice, <i>ex vivo</i> T cell inhibition for xenografts, FC | OKT-3                                 | BE0001-2    |            |
| CD3                              | mouse        | <i>in vitro</i> T cell stimulation/activation   | 17A2                                  | BE0002      |            |
| CD3                              | human        | <i>in vivo</i> T cell depletion in humanized mice, <i>ex vivo</i> T cell inhibition for xenografts, FC  | UCHT1 (Leu-4) (T3)                    | BE0231      |            |
| CD3ε                             | mouse        | <i>in vivo</i> T cell depletion, <i>in vitro</i> T cell stimulation/activation, IF, FC  | 145-2C11                              | BE0001-1    | BP0001-1   |
| CD3ε                             | mouse        | <i>in vitro</i> T cell negative selection, <i>in vitro</i> T cell stimulation/activation, IF  | KT3                                   | BE0261      |            |
| CD3ε F(ab) <sub>2</sub> fragment | mouse        | <i>in vivo</i> T cell depletion   | 145-2C11 f(ab) <sub>2</sub> Fragments | BE0001-1FAB |            |
| CD4                              | mouse        | <i>in vivo</i> CD4 <sup>+</sup> T cell depletion, FC  | GK1.5                                 | BE0003-1    | BP0003-1   |
| CD4                              | human        | <i>in vitro</i> T cell stimulation/activation, <i>in vivo</i> CD4 <sup>+</sup> T cell depletion in humanized mice, FC, IP                             | OKT-4                                 | BE0003-2    |            |
| CD4                              | mouse        | <i>in vivo</i> blockade of CD4 <sup>+</sup> T-cell responses, WB  | YTS 177                               | BE0003-3    |            |
| CD4                              | mouse        | <i>in vivo</i> CD4 <sup>+</sup> T cell depletion  | YTS 191                               | BE0119      |            |
| CD4                              | human        | <i>in vitro</i> CD4 blockade, <i>in vitro</i> blocking of CD4 <sup>+</sup> T cell activation, IF, IHC-F, FC   | RPA-T4                                | BE0288      |            |
| CD4                              | rat          | <i>in vivo</i> CD4 <sup>+</sup> T cell depletion, FC  | OX-38                                 | BE0308      |            |
| CD8 (Lyt 2.1)                    | mouse        | <i>in vivo</i> CD8 <sup>+</sup> T cell depletion, FC  | 116-13.1 (HB129)                      | BE0118      |            |
| CD8α                             | mouse        | <i>in vivo</i> CD8 <sup>+</sup> T cell depletion, IF, FC  | 53-6.7                                | BE0004-1    | BP0004-1   |
| CD8α                             | human        | <i>in vivo</i> CD8 <sup>+</sup> T cell depletion in humanized mice  | OKT-8                                 | BE0004-2    |            |
| CD8α                             | mouse        | <i>in vivo</i> CD8 <sup>+</sup> T cell depletion  | 2.43                                  | BE0061      | BP0061     |
| CD8α                             | mouse        | <i>in vivo</i> CD8 <sup>+</sup> T cell depletion  | YTS169.4                              | BE0117      | BP0117     |
| CD8β (Lyt 3.2)                   | mouse        | <i>in vivo</i> CD8 <sup>+</sup> T cell depletion, <i>in vitro</i> CD8 blockade, IF  | 53-5.8                                | BE0223      |            |
| CD11a (LFA-1α)                   | human        | <i>in vitro</i> LFA-1 neutralization  | TS-1/22.1.1.13                        | BE0005      |            |
| CD11a (LFA-1α)                   | mouse        | <i>in vivo</i> LFA-1 neutralization   | FD441.8                               | BE0005-1    |            |
| CD11a (LFA-1α)                   | mouse        | <i>in vivo</i> LFA-1 neutralization, FC   | M17/4                                 | BE0006      |            |
| CD11a (LFA-1α)                   | human        | Functional assays, FC   | R7-1                                  | BE0192      |            |
| CD11b                            | mouse/human  | <i>in vivo</i> CD11b neutralization, ILC2 cell purification, FC   | M1/70                                 | BE0007      |            |
| CD16/CD32                        | mouse        | <i>in vivo</i> and <i>in vitro</i> Fc receptor blocking   | 2.4G2                                 | BE0307      |            |
| CD18                             | mouse        | <i>in vivo</i> LFA-1 neutralization   | M18/2                                 | BE0009      |            |
| CD19                             | mouse        | <i>in vivo</i> B cell depletion, <i>in vivo</i> CD19 neutralization, <i>in vitro</i> B cell negative selection, FC                                    | 1D3                                   | BE0150      |            |
| CD19                             | human        | FC, Functional assays, IF, Chimeric antigen receptor construction   | 4G7                                   | BE0281      |            |
| CD20                             | mouse        | <i>in vivo</i> B cell depletion, WB   | MB20-11                               | BE0356      | BP0356     |
| CD20                             | human/monkey | <i>in vivo</i> B cell depletion in hCD20 Tg mice, IHC-F, IP, FC   | 2H7                                   | BE0276      |            |
| CD20                             | mouse        | FC, WB  | AISB12                                | BE0302      |            |
| CD22                             | mouse        | <i>in vivo</i> B cell depletion in combination with anti-CD19 (clone 1D3) and anti-rat κ Light Chain (clone MAR 18.5), FC, IP                         | Cy34.1                                | BE0011      |            |
| CD24                             | mouse        | <i>in vivo</i> administration, IHC-F, IHC-P, IF, FC   | M1/69                                 | BE0360      |            |
| CD25 (IL-2Rα)                    | mouse        | <i>in vivo</i> regulatory T cell depletion, FC  | PC-61.5.3                             | BE0012      | BP0012     |
| CD25 (IL-2Rα)                    | human        | IP, IF  | 7G7B6                                 | BE0014      |            |
| CD27                             | mouse        | <i>in vivo</i> CD27 stimulation, <i>in vitro</i> CD27 stimulation, IP, FC   | RM27-3E5                              | BE0348      |            |
| CD28                             | mouse        | <i>in vivo</i> CD28 blockade, <i>in vitro</i> T cell stimulation/activation   | 37.51                                 | BE0015-1    |            |
| CD28                             | mouse        | <i>in vitro</i> T cell stimulation/activation   | PV-1                                  | BE0015-5    |            |
| CD28                             | rat          | <i>in vitro</i> T cell stimulation/activation, FC   | JJ319                                 | BE0040      |            |
| CD28                             | human        | <i>in vitro</i> T cell stimulation/activation   | 9.3                                   | BE0248      |            |
| CD28                             | human/monkey | <i>in vitro</i> T cell stimulation/activation, FC, IHC-F, IP  | CD28.2                                | BE0291      |            |
| CD28                             | mouse        | <i>in vivo</i> and <i>in vitro</i> T cell stimulation/activation  | D665                                  | BE0328      |            |
| CD29                             | mouse        | IF, FC  | KMI6                                  | BE0232      |            |
| CD32 (FcγRIIA)                   | human        | <i>in vivo</i> FcγRIIA blockade in humanized mice, <i>in vitro</i> FcγRIIA blockade, ELISA, FC  | IV.3                                  | BE0224      |            |
| CD38                             | mouse        | <i>in vivo</i> and <i>in vitro</i> CD38 stimulation, <i>in vitro</i> B cell activation, IF  | NIMR5                                 | BE0317      |            |
| CD40                             | mouse        | <i>in vivo</i> CD40 activation, <i>in vitro</i> B cell stimulation/activation   | FGK4.5/FGK45                          | BE0016-2    | BP0016-2   |
| CD40                             | human        | <i>in vitro</i> B cell stimulation, <i>in vitro</i> CD40 stimulation, <i>in vitro</i> macrophage stimulation, Functional assays, FC                   | G28.5                                 | BE0189      |            |
| CD154 (CD40L)                    | mouse        | <i>in vivo</i> and <i>in vitro</i> blocking of CD40/CD40L signaling   | MR-1                                  | BE0017-1    | BP0017-1   |
| CD154 (CD40L)                    | human/monkey | <i>in vitro</i> blocking of CD40/CD40L signaling, <i>in vivo</i> blocking of CD40/CD40L signaling, IP, FC   | 5C8                                   | BE0292      |            |

# CD Marker 体内抗体, CD1...CD370



| 靶标                     | 反应种属            | 应用类型  | 克隆号                 | InVivoMab | InVivoPlus |
|------------------------|-----------------|---|---------------------|-----------|------------|
| CD44                   | mouse/human     | <i>in vivo</i> CD44 neutralization  | IM7                 | BE0039    |            |
| CD44                   | human           | <i>in vivo</i> CD44 blockade in xenografts, <i>in vitro</i> CD44 blockade, WB, IF   | Hermes-1            | BE0262    |            |
| CD45RB                 | mouse           | <i>in vivo</i> anti-CD45RB-mediated tolerance induction, <i>in vivo</i> pre-mNK cell depletion                                | MB23G2 (HB220)      | BE0019    |            |
| CD45.2                 | mouse           | <i>in vivo</i> and <i>in vitro</i> CD45.2 blockade, FC, IHC-F,  | 104.2               | BE0300    |            |
| CD47                   | human           | <i>in vivo</i> CD47 neutralization in human tumor xenograft models or humanized mice, <i>in vitro</i> CD47 neutralization, FC | B6H12               | BE0019-1  |            |
| CD47                   | human/mouse/rat | <i>in vivo</i> and <i>in vitro</i> CD47 blockade, IF  | MIAP410             | BE0283    | BP0283     |
| CD47 (IAP)             | mouse           | <i>in vivo</i> CD47 blockade, <i>in vitro</i> CD47 blockade, IF   | MIAP301             | BE0270    |            |
| CD48                   | mouse           | <i>in vivo</i> and <i>in vitro</i> CD48 blockade  | HM48-1              | BE0147    |            |
| CD49d (VLA-4)          | mouse/human     | <i>in vivo</i> and <i>in vitro</i> VLA-4 neutralization, FC   | PS/2                | BE0071    |            |
| CD54 (ICAM-1)          | mouse           | <i>In vivo</i> ICAM-1 neutralization  | YN1/1.7.4           | BE0020-1  |            |
| CD54 (ICAM-1)          | human           | <i>in vitro</i> T cell stimulation/activation, IF   | R6-5-D6             | BE0020-2  |            |
| CD62E (E-Selectin)     | mouse           | <i>in vivo</i> and <i>in vitro</i> E-selectin blockade, IHC-F   | 9A9                 | BE0294    |            |
| CD62L (L-Selectin)     | mouse           | <i>In vivo</i> CD62L neutralization   | Mel-14              | BE0021    |            |
| CD69                   | mouse           | <i>in vivo</i> down-regulation of CD69 expression, Functional assays  | CD69.2.2            | BE0330    |            |
| CD70                   | mouse           | <i>in vivo</i> and <i>in vitro</i> CD70 blockade, FC  | FR70                | BE0022    |            |
| CD71                   | human           | FC, IHC-F   | OKT9                | BE0023    |            |
| CD71 (TfR)             | human           | WB, IP, FC  | 5E9C11              | BE0343    |            |
| CD71 (TfR1)            | mouse           | <i>in vivo</i> depletion of CD71+ cells   | R17 217.1.3/TIB-219 | BE0175    |            |
| CD71 (TfR1)            | mouse           | <i>in vivo</i> depletion of CD71+ cells, IF, IHC-F, WB  | 8D3                 | BE0329    |            |
| CD71 (TfR1)            | rat/mouse       | Targeted drug delivery to the brain, IHC-F, FC  | OX-26               | BE0331    |            |
| CD73                   | mouse           | <i>in vivo</i> CD73 blockade  | TY/23               | BE0209    |            |
| CD80 (B7-1)            | mouse           | <i>in vivo</i> B7-1 blockade, affinity chromatography   | 1G10                | BE0134    |            |
| CD80 (B7-1)            | mouse           | <i>In vivo</i> CD80 blockade, FC  | 16-10A1             | BE0024    |            |
| CD86 (B7-2)            | mouse           | <i>In vivo</i> CD86 blockade, FC  | GL-1                | BE0025    |            |
| CD90 (Thy1)            | mouse           | <i>in vitro</i> T cell depletion  | M5/49.4.1           | BE0076    |            |
| CD90.1 (Thy1.1)        | mouse           | <i>in vitro</i> T cell depletion  | 19E12               | BE0214    |            |
| CD90.2 (Thy1.2)        | mouse           | <i>in vivo</i> ILC depletion, <i>in vivo</i> T cell depletion   | 30H12               | BE0066    | BP0066     |
| CD91 (LRP1)            | mouse/human/rat | WB, IF, IP  | 11H4                | BE0333    |            |
| CD96                   | mouse           | <i>in vivo</i> and <i>in vitro</i> CD96 blocking, FC  | 3.3                 | BE0337    |            |
| CD103                  | mouse           | <i>In vivo</i> CD103 neutralization, IF, FC   | M290                | BE0026    |            |
| CD106 (VCAM-1)         | mouse           | <i>in vivo</i> VCAM-1 neutralization, IF  | M/K-2.7             | BE0027    |            |
| CD115 (CSF1R)          | mouse           | <i>in vivo</i> macrophage depletion, <i>in vivo</i> monocyte depletion, <i>in vitro</i> CSF-1R neutralization, FC             | AFS98               | BE0213    | BP0213     |
| CD115 (CSF1R)          | human           | <i>in vitro</i> CSF1R neutralization, IHC-P, FC, Functional assays  | 2-4A5-4             | BE0347    |            |
| CD117 (c-Kit)          | mouse           | FC, IF, IHC   | 2B8                 | BE0280    |            |
| CD119 (IFNγR)          | mouse           | <i>in vivo</i> IFNγR neutralization   | GR-20               | BE0029    |            |
| CD119 (IFNγRα)         | mouse           | WB, IP, FC  | 2E2                 | BE0287    |            |
| CD120b (TNFR2)         | mouse           | <i>in vivo</i> TNFR2 blockade, <i>in vitro</i> TNFR2 blockade   | TR75-54.7           | BE0247    |            |
| CD121a (IL-1 R)        | mouse           | <i>in vitro</i> IL-1 R blockade   | JAMA-147            | BE0256    |            |
| CD122 (IL-2Rβ)         | mouse           | <i>in vitro</i> NK cell negative selection, IP, FC  | 5H4                 | BE0272    |            |
| CD122 (IL-2Rβ)         | mouse           | <i>in vivo</i> NK cell depletion, <i>in vitro</i> IL-2R blockade, Functional assays, FC                                       | TM-Beta 1           | BE0298    |            |
| CD127 (IL-7Rα)         | mouse           | <i>in vivo</i> blocking of IL-7Rα signaling, FC   | A7R34               | BE0065    |            |
| CD132 (common γ chain) | mouse           | <i>in vivo</i> γc blockade, Functional assays, IP, FC   | 3E12                | BE0271    |            |
| CD134 (OX40)           | mouse           | <i>in vivo</i> and <i>in vitro</i> OX40 activation  | OX-86               | BE0031    | BP0031     |
| CD134L (OX40L)         | mouse           | <i>in vivo</i> blocking of OX40/OX40L signaling, <i>in vitro</i> OX40L neutralization   | RM134L              | BE0033-1  |            |
| CD137 (4-1BB)          | mouse           | <i>in vivo</i> activation of 4-1BB  | LOB12.3             | BE0169    | BP0169     |
| CD137 (4-1BB)          | mouse           | <i>in vivo</i> and <i>in vitro</i> 4-1BB stimulation  | 3H3                 | BE0239    | BP0239     |
| CD137 (4-1BB)          | mouse           | <i>in vitro</i> 4-1BB blockade, FC  | 17B5                | BE0296    |            |
| CD137L (4-1BBL)        | mouse           | <i>in vivo</i> 4-1BBL blockade  | TKS-1               | BE0110    |            |
| CD152 (CTLA-4)         | mouse           | <i>in vivo</i> and <i>in vitro</i> CTLA-4 neutralization, FC  | UC10-4F10-11        | BE0032    | BP0032     |
| CD152 (CTLA-4)         | mouse           | <i>in vivo</i> and <i>in vitro</i> CTLA-4 neutralization, FC  | 9H10                | BE0131    | BP0131     |
| CD152 (CTLA-4)         | mouse           | <i>in vivo</i> CTLA-4 neutralization  | 9D9                 | BE0164    | BP0164     |

# CD Marker 体内抗体, CD1...CD370



| 如何选择: <i>InVivoMab</i> VS <i>InVivoPlus</i> |                           |                            |
|---|---------------------------|----------------------------|
|   | <i>InVivoMab</i><br>> 95% | <i>InVivoPlus</i><br>> 95% |
| 纯度  |                           |                            |
| 蛋白质聚集 ≤ 5% 验证                               |                           | ✓                          |
| 不含叠氮化钠与载体蛋白                                 | ✓                         | ✓                          |
| 内毒素   | < 2EU/mg                  | < 1EU/mg                   |
| WB, FC, ELISA等应用验证                          |                           | ✓                          |
| 小鼠病原体检测 (无污染)                               |                           | ✓                          |
| 大包装现货                                       | ✓                         | ✓                          |

| 靶标                       | 反应种属         | 应用类型   | 克隆号           | <i>InVivoMab</i> | <i>InVivoPlus</i> |
|--------------------------|--------------|--|---------------|------------------|-------------------|
| CD152 (CTLA-4)           | human        | <i>in vitro</i> CTLA-4 neutralization, FC  | BN13          | BE0190           |                   |
| CD159 (NKG2A/C/E)        | mouse        | <i>in vivo</i> and <i>in vitro</i> NKG2A blockade, IHC-F, FC   | 20D5          | BE0321           |                   |
| CD161 (NK1.1)            | mouse        | <i>in vivo</i> NK cell depletion, FC   | PK136         | BE0036           | BP0036            |
| CD162 (PSGL-1)           | mouse        | <i>in vivo</i> PSGL-1 blockade, IHC-F  | 4RA10         | BE0186           |                   |
| CD172a (SIRPα)           | mouse        | <i>in vivo</i> and <i>in vitro</i> SIRPα blocking, WB, IP, FC  | P84           | BE0322           |                   |
| CD178 (FasL)             | mouse        | <i>in vivo</i> and <i>in vitro</i> FasL blockade, Functional assay, IHC-P, FC                                    | MFL3          | BE0319           |                   |
| CD183 (CXCR3)            | mouse        | <i>in vivo</i> CXCR3 neutralization, FC  | CXCR3-173     | BE0249           |                   |
| CD193 (CCR3)             | mouse        | <i>in vivo</i> eosinophil depletion  | 6S2-19-4      | BE0316           |                   |
| CD200 (OX2)              | mouse        | <i>in vivo</i> and <i>in vitro</i> CD200 blockade, IHC-F, IF, FC   | OX-90         | BE0299           |                   |
| CD209b (SIGN-R1)         | mouse        | <i>in vivo</i> SIGN-R1 blockade, IHC-F, WB, FC   | 22D1          | BE0220           |                   |
| CD210 (IL-10R)           | mouse        | <i>in vivo</i> blocking of IL-10/IL-10R signaling, <i>in vitro</i> blocking of IL-10R signaling, FC              | 1B1.3A        | BE0050           | BP0050            |
| CD220 (Insulin Receptor) | human        | WB   | IR 83-22      | BE0338           |                   |
| CD223 (LAG-3)            | mouse        | <i>in vivo</i> and <i>in vitro</i> LAG-3 neutralization, FC  | C9B7W         | BE0174           | BP0174            |
| CD227 (MUC1)             | human        | <i>in vivo</i> administration in mouse xenograft models, <i>in vitro</i> cell cytotoxicity assay, WB, IHC-P, IF, | C595 (NCRC48) | BE0336           |                   |
| CD243 (MDR-1)            | human/monkey | <i>in vivo</i> MDR-1 blocking/depletion in xenogeneic murine tumor models, <i>in vitro</i> MDR-1 blocking, IHC-P | UIC2          | BE0340           |                   |
| CD254 (RANKL)            | mouse        | <i>in vivo</i> RANKL blockade  | IK22/5        | BE0191           |                   |
| CD262 (DR5)              | mouse        | <i>in vivo</i> and <i>in vitro</i> induction TRAIL-mediated apoptosis  | MDS-1         | BE0161           |                   |
| CD272 (BTLA)             | mouse        | <i>in vivo</i> BTLA stimulation, <i>in vivo</i> BTLA blockade  | 6A6           | BE0132           |                   |
| CD272 (BTLA)             | mouse        | <i>in vivo</i> and <i>in vitro</i> stimulation of BTLA, FC   | PK18.6        | BE0153           |                   |
| CD272 (BTLA)             | mouse        | <i>in vivo</i> BTLA blockade, <i>in vitro</i> T cell stimulation/activation, FC                                  | PJ196         | BE0196           |                   |
| CD272 (BTLA)             | mouse        | <i>in vivo</i> BTLA+ B cell and CD4 T cell depletion, FC   | 6F7           | BE0304           |                   |
| CD273 (PD-L2)            | mouse        | <i>in vivo</i> and <i>in vitro</i> PD-L2 blockade, IHC-F, FC   | TY25          | BE0112           |                   |
| CD274 (PD-L1)            | mouse        | <i>in vivo</i> PD-L1 blockade, IF, IHC-F, FC   | 10F.9G2       | BE0101           | BP0101            |
| CD275 (ICOSL)            | mouse        | <i>in vivo</i> ICOSL neutralization  | HK5.3         | BE0028           |                   |
| CD276 (B7-H3)            | mouse        | <i>in vivo</i> B7-H3 blockade, FC  | MJ18          | BE0124           |                   |
| CD278 (ICOS)             | mouse        | <i>in vivo</i> blocking of ICOS/ICOSL signaling, FC  | 7E.17G9       | BE0059           |                   |
| CD279 (PD-1)             | mouse        | <i>in vivo</i> blocking of PD-1/PD-L signaling, <i>in vitro</i> PD-1 neutralization                              | J43           | BE0033-2         | BP0033-2          |
| CD279 (PD-1)             | mouse        | <i>in vivo</i> blocking of PD-1/PD-L signaling   | RMP1-14       | BE0146           | BP0146            |
| CD279 (PD-1)             | human        | <i>in vitro</i> PD-1 neutralization, <i>in vivo</i> PD-1 blockade in humanized mice                              | J116          | BE0188           |                   |
| CD279 (PD-1)             | human        | <i>in vivo</i> PD-1 blockade in humanized mice, FC   | J110          | BE0193           |                   |
| CD279 (PD-1)             | mouse        | <i>in vivo</i> blocking of PD-1/PD-L signaling, <i>in vitro</i> PD-1 neutralization, IHC-F, FC, WB               | 29F.1A12      | BE0273           | BP0273            |
| CD314 (NKG2D)            | mouse        | <i>in vivo</i> and <i>in vitro</i> NKG2D blockade, FC  | CX5           | BE0334           |                   |
| CD317 (BST2, PDCA-1)     | mouse        | <i>in vivo</i> pDC depletion, IF, FC   | 927           | BE0311           |                   |
| CD324 (E-Cadherin)       | mouse        | <i>in vivo</i> E-Cadherin neutralization, <i>in vitro</i> E-Cadherin neutralization, IF, IP, WB                  | DECMA-1       | BE0352           |                   |
| CD326 (EpCAM)            | mouse        | WB, IF, IHC-F, FC  | G8.8          | BE0346           |                   |
| CD340 HER2 (neu)         | human/rat    | <i>in vivo</i> and <i>in vitro</i> HER2/neu inhibition, IP, IF, FC   | 7.16.4        | BE0277           |                   |
| CD365 (TIM-1)            | mouse        | <i>in vivo</i> TIM-1 neutralization  | RMT1-10       | BE0113           |                   |
| CD366 (TIM-3)            | mouse        | <i>in vivo</i> TIM-3 neutralization, <i>in vitro</i> TIM-3 blocking, FC  | RMT3-23       | BE0115           | BP0115            |
| CD366 (TIM-3)            | mouse        | <i>in vivo</i> TIM-3 neutralization, <i>in vitro</i> TIM-3 blocking, FC  | B8.2C12       | BE0275           |                   |
| CD370 (CLEC9A)           | mouse        | <i>in vivo</i> Ag targeting to CLEC9A+ DCs, WB, ELISA, IP, IF, FC  | 7H11          | BE0305           |                   |

IF Immunofluorescence | IHC-F Immunohistochemistry (frozen) | IHC-P Immunohistochemistry (paraffin) | WB Western blot | IP Immunoprecipitation | FC Flow cytometry (requires fluochrome conjugation)



Bio X Cell 中国区总代理:

艾美捷科技

400-6800-868

www.amyjet.com

